Macular degeneration Archives

Home Macular degeneration

Latest Posts

News and Trends 1 Dec 2022

FDA clears SparingVision’s investigational new drug application to treat ocular diseases

SparingVision today announces that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug application (IND) for SPVN06. The genomic medicine company has had its developing vision-saving treatments for ocular diseases, lead gene independent therapy for the treatment of retinitis pigmentosa (RP), a form of rod-cone dystrophy (RCD) and the most prevalent […]

December 1, 2022 - 4 minutesmins - By Liza Laws

More News! 10 Nov 2022

Eye disease therapies being developed after Breye Therapeutics’ €4M seed financing

Breye Therapeutics ApS a biopharmaceutical company developing therapies for retinal vascular diseases today (November 10) has closed a seed financing of €4 million led by Novo Holdings and Sound Bioventures. Diabetic retinopathy (DR) affects approximately 30% of all patients with diabetes and is the leading cause of blindness among working-age adults. Age-related macular degeneration (AMD) […]

November 10, 2022 - 4 minutesmins - By Liza Laws

News and Trends 14 Sep 2022

SparingVision raises €75M for genomic medicines for ocular diseases

SparingVision, a genomic medicine company developing vision-saving treatments for ocular diseases, has raised €75 million ($75 million) in series B financing. The round was co-led by Jeito Capital and UPMC Enterprises, with additional participation from 4BIO Capital, Bpifrance, the RD fund, venture arm of Foundation Fighting Blindness, and Ysios Capital. Proceeds from the financing will […]

September 14, 2022 - 3 minutesmins - By Jim Cornall

Horizone Therapeutics, Eye disease, eye, eyes

News and Trends 9 Sep 2022

Improved vision with less eye injections for patients after primary endpoints met in trials

The primary endpoints in two clinical trials investigating drug aflibercept 8 mg with 12 and 16-week dosing regimes, for patients with diabetic macular edema (DME) and wet age-related macular degeneration (wAMD), have been met. The trials, called PHOTON in DME and PULSAR in wAMD, both showed the dosing regimens achieved non-inferiority in vision gains compared […]

September 9, 2022 - 3 minutesmins - By Liza Laws

News and Trends 15 Aug 2022

Opthea secures up to $170M in financing for wet AMD treatment

Opthea Limited, a clinical-stage biopharma company developing novel therapies to treat highly prevalent and progressive retinal diseases, has announced a non-dilutive financing transaction for up to US$170 million from investment funds working with Launch Therapeutics (Launch Tx) to finance and advance the ongoing phase 3 clinical trials and pre-commercialization activities of OPT-302 for wet age-related […]

August 15, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 3 Aug 2022

Full label approval given by FDA for eye disease drug, CIMERLI

Age-related neovascular (wet) macular degeneration (nAMD) and other serious retinal diseases can now be treated after the U.S. Food and Drug Administration (FDA) approved a biosimilar product interchangeable with an injection. The approval of CIMERLI (ranibizumab-eqrn) interchangeable with Lucentis, a ranibizumab injection was jointly announced by Polpharma Biologics BV, Formycon AG and Bioeq AG today […]

August 3, 2022 - 4 minutesmins - By Liza Laws

News and Trends 6 Jul 2022

Finnish and US companies form exclusive agreement for development of sustained release drug

A sustained release drug that can help people with age-related macular degeneration (AMD) has been given a global license agreement. DelSiTech and Iveric Bio have announced the agreement so Iveric Bio can develop and commercialize new formulations of drug Zimura (avacincaptad pegol) using DelSiTech’s silica-based sustained release technology. As part of Iveric Bio’s lifecycle expansion […]

July 6, 2022 - 4 minutesmins - By Liza Laws

Resources

Categories

The biggest private biotech investments in August 2024

Long non-coding RNAs: what’s behind the growing “dark genome” buzz?

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

Six biotech companies that could revolutionize obesity treatments

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us